Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Article Date
October 1, 2024
This article is featured on another website.
Go to article
January 26, 2026
Maximizing Global Study Value: Clinical Trial Landscapes in South Korea and Japan
Clinical trial globalization continues to be a major trend for industry-sponsored clinical trials. More recently,…
January 26, 2026
Maximizing Global Study Value: Clinical Trial Landscapes in South Korea and Japan
Clinical trial globalization continues to be a major trend for industry-sponsored clinical trials. More recently,…
January 26, 2026
Understanding the US FDA’s Special Designations and Approval Pathways
Recognizing the challenges of drug development, the US FDA has established several special designations and…
January 26, 2026
Understanding the US FDA’s Special Designations and Approval Pathways
Recognizing the challenges of drug development, the US FDA has established several special designations and…